LLY
Lilly’s newest weight-loss flex
Eli Lilly came out Thursday with topline Phase 3 data on retatrutide, its triple-hormone obesity drug, and the numbers are the kind that make Wall Street sit up straight. In the TRIUMPH-1 trial, patients on the 12 mg dose lost 28.3% of body weight after 80 weeks — roughly 70.3 pounds on average. Not exactly a casual “I skipped dessert” result.
Why investors care
This matters because obesity is still one of pharma’s juiciest battlegrounds, and Lilly is trying to keep its lead in the GLP-1 gold rush. The company said all doses hit the study’s primary and key secondary endpoints, which is the sort of sentence that can turn into a very expensive champagne cork pop in Indianapolis.
- The 9 mg dose produced a 25.9% average weight loss.
- The 4 mg dose still delivered a hefty 19% drop.
- In a blinded extension, patients staying on 12 mg through 104 weeks lost 30.3% of body weight on average.
Not just scale drama
Lilly also said retatrutide improved a bunch of cardiovascular risk markers, including waist circumference, triglycerides, systolic blood pressure, and hs-CRP. Translation: this isn’t just a vanity metric story. It’s about whether the drug can become a broad metabolic workhorse, not just another needle in the shrinking waistline aisle.
The runway ahead
The company plans to show more TRIUMPH-1 data at the upcoming American Diabetes Association Scientific Sessions, and later this year it expects more readouts from TRIUMPH-2 and TRIUMPH-3, which are looking at Type 2 diabetes and cardiovascular disease. Big picture: Lilly just reminded the market that its obesity franchise is still very much in the driver’s seat.